Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Photos: Hundreds Gather at Bondi Beach After Deadly Attack - 2Washington resident contracts bird flu, first human case in U.S. since February
- 3Step by step instructions to Keep up with the Life span of Your Kona SUV's Battery Duration
- 4Moscow: Russia well-positioned to withstand oil market shocks
- 5Flourishing in a Cutthroat Work Market: Vocation Methodologies
- Arrow Exploration brings new Colombian oil well on stream ahead of schedule and under budget
- Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- Winter storm warnings issued across Northeast as up to 9 inches of snow forecast; deadly atmospheric river in California snarls travel
- China and Pakistan issue five-point peace plan for Middle East
- Vote In favor of Your Favored Web based Dating Application
- SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
- Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces
- Venezuelan President Maduro arrives in New York following U.S. capture: Full coverage
- Geomagnetic storm grounds launch of Mars space weather satellites
